Press Releases

Celleron Therapeutics announces James Noble as a New Board Member

Oct 21, 2019

Oxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today

Celleron Therapeutics presents CXD101 and nivolumab combination therapy Phase II clinical trial (CAROSELL) at ESMO 2019

Sep 30, 2019

Oxford, UK, 30th September 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,

Celleron Therapeutics to present CXD101 and nivolumab combination therapy Phase II clinical trial (CAROSELL) at ESMO 2019

Aug 6, 2019

Oxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,

Celleron Therapeutics Data Committee approves continuation of CXD101 and nivolumab combination therapy CAROSELL Phase II clinical trial in MSS CRC patients

Jun 17, 2019

Oxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval

Celleron Therapeutics Presents at the 15th Shanghai International Colorectal Cancer Symposium (SICCS)

Jun 15, 2019

Oxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that

Celleron Therapeutics discusses China as a Biotech Hot Spot, at BioEquity Europe 2019

May 24, 2019

Oxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the

Celleron Therapeutics CXD101 and nivolumab combination therapy CAROSELL clears initial Phase II clinical trial efficacy hurdle in MSS CRC patients

Apr 16, 2019

Oxford, UK, 16 April 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today the